Treatment testicular cancer new improved model Testicular cancer model curable neoplasm Prior advent cisplatin combination chemotherapy standard chemotherapy dactinomycin combination chlorambucil methotrexate germ cell tumors chemosensitive regimens objective response rate complete remission rate cure rate initial cisplatin vinblastine bleomycin PVB chemotherapy patients disseminated germ cell tumors complete remission CR additional disease-free post-PVB resection teratoma carcinoma Twenty-seven patients disease-free minimal follow-up years cisplatin-based chemotherapy one-log increase cure rate dactinomycin subsequent phase III study vinblastine dosage mg/kg mg/kg reduction toxicity decrement therapeutic efficacy third-generation PVB study optimal cure rates weeks induction therapy PVB long-term maintenance therapy vinblastine unnecessary salvage therapy cisplatin etoposide patients PVB patients regimen first time adult solid tumor second-line regimen studies third-line therapy cisplatin ifosfamide combination chemotherapy refractory setting patients curable cisplatin bleomycin PVB first-line chemotherapy significant reduction neuromuscular toxicity arm patients disease-free PVB patients disseminated germ cell tumors additional curable salvage chemotherapy cure rate adult malignancy 